Women with Complex Vascular Anomalies: Impact on Contraception, Pregnancy and Reproductive Health.

Background: Literature is scarce regarding contraceptive and reproductive health in women with complex vascular anomalies (VA).

Objectives: To assess obstetrical, gynecological and reproductive health in this population.

Methods: Female adult patients of childbearing age from the VA clinic of a single tertiary care centre in Canada have been recruited by retrospective chart review, and administered phone interviews.

Pediatric Lymphedema: Study of 180 Patients Referred to a Tertiary Lymphedema Clinic.

Background: Lymphedema is due to dysfunction of the lymphatic system. It can be primary or secondary. Pediatric lymphedema is more often primary and is a chronic disease with a heavy burden on quality of life.

Non-involuting congenital hemangiomas (NICH) with postnatal atypical growth: A case series.

Background: Non-involuting congenital hemangiomas (NICH) are fully formed vascular tumors at birth, with a distinctive clinical, radiologic, and histopathological profile, and classically lack expansion or involution over time. We describe a series of NICH cases with atypical postnatal growth.

Methods: The authors retrospectively analyzed all NICH cases diagnosed from 2007 to 2017.

Quality of life in pediatric patients before and after cosmetic camouflage of visible skin conditions.

Background: Visible vascular and pigmentary conditions have a negative impact on children's and adolescents' quality of life (QoL). We sought to quantitate the effect of visible skin anomalies and their camouflage on QoL.

Methods: In all, 41 patients, 5 years of age and older, were taught to use cosmetic camouflage.

Late rebound of infantile hemangioma after cessation of oral propranolol.

Propranolol has become the first line of treatment for infantile hemangiomas (IHs), with a high response rate, but rebound growth after cessation of propranolol has been reported, primarily in the first year of life. We sought to determine the frequency and associated factors leading to late regrowth after successful treatment at an age when the proliferative phase has usually ceased. We retrospectively reviewed the clinical charts, serial photographs, and radiologic images of children with rebound IH occurring after the age of 15 months after a successful course of oral propranolol averaging 2.

Therapy of ulcerated hemangiomas.

Background: Cutaneous ulceration is the most common complication of infantile hemangiomas (IHs) seen in a pediatric dermatology practice.

Objective: The most effective treatments in our experience are compared to those in the current literature.

Methods: The study was a retrospective chart review of therapy of 169 ulcerated IHs at a tertiary care pediatric hospital and a literature review.

Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.

Background: Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH.

Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality.

Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.

Background: Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH.

Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality.

Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study.

The goal of the current study was to compare the clinical effectiveness of oral propranolol with that of oral prednisone in the treatment of infantile hemangiomas (IH). Patients treated for IH with oral propranolol were retrospectively matched with patients treated with oral prednisone according to type, location, and size of the IH and age at start of treatment. Response to treatment was evaluated by rating serial medical photographs taken 1, 2, and 6 months after initiation of treatment.